5YL Stock Chart & Stats
€0.04
€0.00(0.00%)
At close: 4:00 PM EST
€0.04
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.02 - €0.13
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€29.08M
Enterprise Value€158.22M
Total Cash (Recent Filing)€51.40M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 12, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding394,878,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)0.85
Price to Sales (P/S)4.14
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€4.89M
Bulls Say, Bears Say
Bulls Say
Conservative Capital StructureZero reported debt and substantial equity reduce solvency risk and provide financial flexibility over the medium term. A low-leverage balance sheet lengthens runway versus highly levered peers, enabling continued product investments or M&A without immediate refinancing pressure.
Focused Clinical Product PortfolioA clear focus on hospital TTM and proprietary cooling systems targets durable demand in acute and critical care. Hospital settings create higher switching costs and recurring consumable purchases, supporting steady installed-base revenue and long-term commercial relationships with clinical buyers.
Proven Commercial Scaling (historical)Material revenue growth through 2024 shows the company can commercialize its products and penetrate clinical markets. Historical scaling demonstrates product-market fit and sales execution capability that can be re-leveraged if operational issues are addressed or market investments resume.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow at material levels implies ongoing reliance on external funding to sustain operations. Over months this erodes equity, constrains R&D and commercialization spend, and raises execution risk if new funding terms are unfavorable or delayed.
Ongoing Unprofitability And Poor Unit EconomicsNegative TTM gross margin indicates the business is not yet producing sustainable unit economics. Without improvement in cost structure, pricing, or scale, profitability remains out of reach, undermining long-term cash generation and forcing strategic trade-offs between growth and margin recovery.
Recent Revenue Momentum DeteriorationA reversal from prior growth to declining revenue in 2025 and a sharp TTM drop weakens the growth narrative and pressures unit economics. Falling top-line makes it harder to achieve scale-related margin improvements and increases near-term financing needs to maintain market presence.
BrainCool AB News
5YL FAQ
What was BrainCool AB’s price range in the past 12 months?
BrainCool AB lowest stock price was €0.02 and its highest was €0.13 in the past 12 months.
What is BrainCool AB’s market cap?
BrainCool AB’s market cap is €29.08M.
When is BrainCool AB’s upcoming earnings report date?
BrainCool AB’s upcoming earnings report date is Aug 12, 2026 which is in 33 days.
How were BrainCool AB’s earnings last quarter?
BrainCool AB released its earnings results on May 06, 2026. The company reported €0 earnings per share for the quarter, the consensus estimate of €0 by €0.
Is BrainCool AB overvalued?
According to Wall Street analysts BrainCool AB’s price is currently Overvalued.
Does BrainCool AB pay dividends?
BrainCool AB does not currently pay dividends.
What is BrainCool AB’s EPS estimate?
BrainCool AB’s EPS estimate is 0.
How many shares outstanding does BrainCool AB have?
BrainCool AB has 394,878,140 shares outstanding.
What happened to BrainCool AB’s price movement after its last earnings report?
BrainCool AB reported an EPS of €0 in its last earnings report, expectations of €0. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of BrainCool AB?
Currently, no hedge funds are holding shares in DE:5YL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BrainCool AB
BrainCool AB (publ), a medical technology company founded in 2010 and headquartered in Lund, Sweden, focuses on the development, commercialization, and distribution of advanced medical cooling systems. Operating with its subsidiaries, the company caters to the healthcare sector, primarily serving the Swedish market, by providing innovative solutions for various conditions including stroke, sudden cardiac arrest, oral mucositis, and migraine. Their product line features the BrainCool and RhinoChill systems, specifically engineered to deliver swift therapeutic cooling in emergency situations, thereby ensuring uninterrupted patient care. To mitigate the risk of oral mucositis, BrainCool offers the Cooral system, renowned for its user-friendly design for medical professionals. Furthermore, the IQool system boasts an intuitive interface complemented by informative graphics and an automatic feedback loop, empowering clinicians to dedicate their attention to patient management rather than device operation.
Technical Analysis
Bactiguard Holding AB
―
C-Rad AB Class B
―
Acarix AB
―
Sedana Medical AB
―
Mentice AB
―